source
- Avalo's Phase 2 data lifts shares 45% as skin drug shows 42% response in hidradenitis suppurativaAvalo Therapeutics reported that its experimental therapy abdakibart met the primary goal of a Phase 2 trial in patients with hidradenitis suppurativa. Both low and high dose groups achieved respon…
- Novo Nordisk reports 1 million Wegovy patients and 2.3 bn DKK sales in Q1 amid pricing pressureNovo Nordisk's CEO Mike Doustad said the company saw about one million patients using its obesity drug Wegovy during the first quarter. The pill generated sales of roughly 2.3 billion Danish krone…